Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, rituximab (MabThera®) cannot be endorsed for use within NHS Wales in combination with glucorticoids for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegeners) (GPA) and microscopic polyangiitis (MPA) |
||
|
||
Medicine details |
||
| Medicine name | rituximab (MabThera®) | |
| Formulation | 100 mg concentrate for solution for infusion, 500 mg concentrate for solution for infusion | |
| Reference number | 3517 | |
| Indication | For use in combination with glucorticoids for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegeners) (GPA) and microscopic polyangiitis (MPA) |
|
| Company | Roche Products Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 09/05/2019 | |
| Date of last review | 14/05/2019 | |